ILDEX Vietnam 2010 is ready to offer technology and business solutions for Vietnam’s livestock, dairy, meat-processing, and aquaculture industries according to NEO - - the organizer of ILDEX Vietnam 2010 which will take place on March 25-27, 2010 at the New Saigon Exhibition and Convention Center, Ho Chi Minh City, Vietnam.
N.C.C. Exhibition Organizer Co., Ltd., (NEO) announced the readiness of ILDEX Vietnam 2010 which will take place on March 25-27, 2010 at the New Saigon Exhibition and Convention Center in Ho Chi Minh City, Vietnam. At the Kick-off Launching of ILDEX Vietnam 2010, Ms. Ladda Mongkolchaivivat, General Manager, N.C.C. Exhibition Organizer (NEO) told industry representative that “ILDEX Vietnam 2010 will be the largest livestock exhibition in Vietnam. It will be a technology showcase of 125 companies from 22 countries including country pavilion from France, Singapore, Korea, China, Shanghai City, and the Netherlands. A number of international governmental and industrial bodies such as Korean Animal Health Products Association, Canadian Swine Association, British Pig Association, Vietnam Department of Animal Health, Vietnam Department of Livestock Production and CCPIT Shanghai have confirmed their participation at this industrial event.”
With heavy promotion campaign and full government support especially from the Ministry of Agricultural and Rural Development of Vietnam, NEO believes that ILDEX Vietnam 2010 will attract a lot of traders and buyers from over 46 cities and provinces surrounding Ho Chi Minh City. Free shuttle service will be provided for trade visitors from those areas.
ILDEX Vietnam 2010 comes in perfect timing as Vietnam livestock, dairy, meat-processing, and aquaculture industries are searching for new technology and business solutions to move the industry to the next level.
Aiming to provide the industry representative with clearer perspective of Vietnam livestock and aquaculture industries, ILDEX invited Professor Hoang Kim Giao, Director of Department of Livestock Production, Ministry of Agriculture and Rural Development and Mr. Nguyen Van Trong, Vice Director-General, Aquaculture Research Institute II of Vietnam to give keynote speeches on “Husbandry in Vietnam – Current Status and Development Goals” and “Overview Aquaculture in Vietnam” respectively.
Prof. Hoang Kim Giao underlined the important of Vietnam livestock industry. However, he said that “it is time for Vietnam to change the structure of its agriculture and rural development. Priority should be given to development of livestock industry including industrialization of livestock farming and food production management to produce high-quality livestock products that meet international food safety standard and enough to serve rising domestic and export demands. Equally important is to protect the natural environment for sustainable development.”
Mr. Nguyen Van Trong echoed the needs for technology and modern business solutions for Vietnam aquaculture industry. Although fish and shrimp have been growing rapidly, both have been facing continuous challenges especially rising production costs, lowering prices and disease management. “Our aquaculture industry might be growing a little too fast especially for catfish farming. The industry must seriously look into sustainable farming management. This time around, the emphasis should be on quality rather than quantity to ensure that growth will continue at sustainable pace. Pangasius for example, we are having market problems so while expanding into new markets we need to be certain that Vietnam’s products meet safety standards and food hygiene, required by importers.”
Apart from technology and business solutions on the exhibition floors, ILDEX Vietnam Aquaculture Conference 2010 under the theme ‘the new dimensions for Vietnam Aquaculture Industry’ will be a good education forum for stakeholders along the production chain from pond/hatchery operators to technical level personnel to managers, feed manufacturers, government officers to grasp the issues facing by the industry and develop suitable policies and aquaculture suppliers supporting the industry.
For more information of ILDEX Vietnam 2010 and ILDEX Vietnam Aquaculture Conference 2010, please contact Mr. Lertwat Chanthatarath – Senior Sales Manager at Tel: +66 2 203 4261-4, E-mail: lertwat@Qsncc.com or visit www.ildex.com
NOTES FOR EDITOR
About ILDEX VIETNAM:
ILDEX, the international trade show series of N.C.C. Exhibition Organizer Co., Ltd., (NEO), is widely known as the International Livestock, Dairy, Meat processing, and Aquaculture Exhibition. The series was first launched in 2006 in 3 emerging agricultural countries in Asia namely Vietnam (ILDEX Vietnam), India (ILDEX India), and China (ILDEX China). Today, ILDEX expands it coverage to offer effective business platforms in the Philippines, and will be from 2011 for the Indonesian market.
ILDEX Vietnam 2010 is the 3rd edition of ILDEX Vietnam series that NEO organizes in corporations with VNU Exhibitions Europe from Holland, and Minh Vi Exhibition and Advertising Services (VEAS) - its local partner. The show is supported by Department of Livestock Production - Ministry of Agriculture and Rural Development of Vietnam (MARD), and will take place on 25-27 March 2010 at The New Saigon Exhibition and Convention Center (SECC), Phu My Hung, HCMC, Vietnam.
About NEO:
N.C.C. Exhibition Organizer Co., Ltd. (NEO) is an experienced, full-fledged professional exhibition organizer handling both domestic and international events with the strong commitment to deliver non-stop creativity, initiated by a team of professionals and to become the leading organizer of international trade and consumer exhibitions in Southeast Asia. For more information please visit www.nccexhibition.com
Sunday, February 7, 2010
Friday, February 5, 2010
WHO HAILS NEW GATES FOUNDATION SUPPORT FOR DECADE OF VACCINES
The World Health Organization welcomes the Bill & Melinda Gates Foundation pledge of US$ 10 billion over the next ten years to accelerate global vaccine efforts.
"The Gates Foundation’s commitment to vaccines is unprecedented, but needs to be matched by unprecedented action. It’s absolutely crucial that both governments and the private sector step up efforts to provide life-saving vaccines to children who need them most," said Dr Margaret Chan, WHO Director-General.
Vaccines and immunization have played a major role since the last century in overall health gains. Smallpox has been eradicated, polio is on the verge of being eradicated and more than 2 million deaths are averted each year.
"Building on these achievements, we can take immunization to the next level, with the expanded uptake of new vaccines against major killers such as pneumonia and rotavirus diarrhoea," said Dr Chan. "An additional two million deaths in children under five years could be prevented by 2015 through widespread use of new vaccines and a 10% increase in global vaccination coverage."
Vaccines join other proven measures, such as micronutrient supplements, oral rehydration therapy, and community delivery of antibiotics, that form an integrated approach to child health and have already brought much progress.
The Bill & Melinda Gates Foundation announcement comes on the tenth anniversary of the establishment of the Global Alliance for Vaccines and Immunization (GAVI). Dr Chan also congratulated the GAVI Alliance on their accomplishment of reaching 257 million additional children with new and underused vaccines.
"The Gates Foundation’s commitment to vaccines is unprecedented, but needs to be matched by unprecedented action. It’s absolutely crucial that both governments and the private sector step up efforts to provide life-saving vaccines to children who need them most," said Dr Margaret Chan, WHO Director-General.
Vaccines and immunization have played a major role since the last century in overall health gains. Smallpox has been eradicated, polio is on the verge of being eradicated and more than 2 million deaths are averted each year.
"Building on these achievements, we can take immunization to the next level, with the expanded uptake of new vaccines against major killers such as pneumonia and rotavirus diarrhoea," said Dr Chan. "An additional two million deaths in children under five years could be prevented by 2015 through widespread use of new vaccines and a 10% increase in global vaccination coverage."
Vaccines join other proven measures, such as micronutrient supplements, oral rehydration therapy, and community delivery of antibiotics, that form an integrated approach to child health and have already brought much progress.
The Bill & Melinda Gates Foundation announcement comes on the tenth anniversary of the establishment of the Global Alliance for Vaccines and Immunization (GAVI). Dr Chan also congratulated the GAVI Alliance on their accomplishment of reaching 257 million additional children with new and underused vaccines.
Friday, January 29, 2010
Counsyl Test to Prevent Diseases Like Those in 'Extraordinary Measures' Now at 100+ Medical Centers
Free with Insurance, New Pre-Pregnancy Test Saves Lives While Dramatically Cutting Health Care Costs
Genetic diseases like those seen in the new Harrison Ford movie "Extraordinary Measures" can now be prevented with a simple saliva test which is free with insurance for more than 100 million Americans.
The movie centers on the real-life efforts of the Crowleys, a family trying to find a cure for a rare genetic disease affecting two of the family’s three children. The condition wasn’t detected until after their children were born.
Now, couples can take a Universal Genetic Test before pregnancy to determine whether their baby is at risk for more than 100 life-threatening genetic diseases. At-risk couples may then use a well-understood procedure called IVF/PGD to protect their child from genetic disease and ensure a healthy pregnancy.
This Universal Genetic Test was invented by scientists and social entrepreneurs from Stanford and Harvard and brought to the public via a Stanford startup named Counsyl (counsyl.com). As Newsweek recently reported:
“What is the secret to improving public health while cutting costs? The question has consumed Washington, but it's being answered elsewhere, by doctors offering a new test for more than 100 rare recessive genes, some of which cause fatal diseases. The test, [offered by] Counsyl, lets potential parents assess their genomes to see if their future kids are at risk. ... This is as preventive as medicine gets: the test could eliminate all single-recessive-gene diseases.”
The test is now offered by physicians at more than 100 prestigious medical centers across the United States, including Yale Fertility Center (see counsyl.com/map), and has attracted the support of prominent academics, bioethicists,
religious leaders, families with genetic disease, and doctors from America’s largest hospitals.
Broad Support among Prominent Physicians for Universal Genetic TestingDr. Steven Ory, Past President of the American Society for Reproductive Medicine: "After 30 years in reproductive medicine, I am more optimistic about this development in genetic disease prevention than I've ever been before. The vast majority of babies born with genetic disease have no family history. That's why it's so critically important for all parents to get the Universal Genetic Test before pregnancy."
Dr. Pasquale Patrizio, Director of the Yale Fertility Center: "Every adult of reproductive age needs the Counsyl test. It is unusual in that it benefits all three parts of the health care triad: patients, doctors, and insurers. A child stricken by
preventable genetic disease often dies in infancy and costs the bereaved parents millions in medical bills. A five minute saliva test that prevents this is a money saver, a time saver, and most importantly a life saver; it really is a no-brainer."
Dr. Thomas Walsh, Director of the Male Fertility Laboratory at the University of Washington: "Genetic testing has been recommended for all adults before pregnancy since 2001, but like many topics related to planning a pregnancy, awareness of this
issue continues to lag. This test covers several key genetic diseases, including cystic fibrosis, spinal muscular atrophy, sickle cell, Tay-Sachs, and many others. The results of testing enable couples to make an informed decision before conceiving a child.”
Dr. John Marshall, Former Chairman of Ob/Gyn at Harbor-UCLA Medical Center: "Because the test can be taken in the privacy of one's home as well as in a clinical setting, it reminds me of the first 'at home pregnancy test'. This 'at home carrier test' is very similar in that the healthy adults who take it generally
test negative, with those who test positive referred for medical followup. It thus completely reshapes the debate over so-called direct-to-consumer or 'DTC' testing. Offering this test over the web as well as in a clinical setting is simply a moral imperative, as it is the only way to get needed care to people in rural areas who may be far away from large hospitals."
Dr. Michael Levy, Clinical Professor of Ob/Gyn at Georgetown & Director of IVF at Shady Grove Fertility, America's largest IVF center: "Parents who know their carrier status before pregnancy can take preventive measures to have a healthy
child. Because new techniques like PGD are used before pregnancy, they avoid the ethical dilemma of termination that was previously a roadblock to wider adoption of carrier testing."
The New Standard of Care at the Nation's Largest Fertility CentersDr. Angeline Beltsos, Medical Director of the Fertility Centers of Illinois: "Every doctor and patient wants to avoid a high-risk pregnancy. Yet many people don't know that
single gene disorders now account for more than 10% of infant deaths. The Universal Genetic Test is the next ultrasound: a non-invasive early warning system for couples to know if their baby is at risk."
Dr. Arthur Wisot, Medical Director of Reproductive Partners Medical Group in Los Angeles: "The Counsyl test is appropriate for everyone trying to conceive because it is the first test that makes it both practical and economical to screen for so
many genetic diseases. Couples can now protect their baby from developing any one of over a hundred debilitating and lethal genetic diseases with just a saliva sample. This test is the future of genetic screening."
Dr. Ian Hardy, Medical Director of Fertility Centers of New England: "We have been offering the Counsyl test to our incoming patients as part of their standard
evaluation with exceptional results. It is an easy-to-use saliva test which is covered by most insurance plans and allows couples to be screened for both common genetic diseases (like CF, SMA, PKU, and beta thalassemia) as well as dozens of rare conditions."
Dr. Kaylen Silverberg, Medical Director of Texas Fertility: "The Counsyl test replaces a battery of more expensive blood tests. It provides a couple and their physician with much more information for a fraction of the cost. Counsyl testing
represents a quantum leap forward in pre-pregnancy planning for couples — especially those concerned about having a child with a genetic disease — as it is safe, affordable, and easy to use."
Dr. Michael Soules, Medical Director of Seattle Reproductive Medicine: "The new Counsyl test is the simplest and most cost-effective way to do genetic screening as it checks for over 100 significant disorders with a single saliva sample. Enlightened insurance carriers are paying for this test as it saves them the major future expenses of covering a chronically sick child."
An Advance for Women, Minorities, and Families with Genetic Disease Professor Henry Louis Gates of Harvard University: "As the first genetic test for all ethnic groups, the Counsyl test represents a genuine breakthrough for minority health. With
one test for diverse communities, African Americans and Hispanics can benefit from a new technology that actually reduces health care disparities."
Elena Ashkinadze, Program Supervisor in Genetics, UMDNJ-Robert Wood Johnson Medical School: "Because Counsyl's test simultaneously covers diseases from many ethnic groups at a considerably lower cost than standard blood tests, it promises to make carrier testing affordable for previously underserved patient populations, including African Americans and Hispanics. The current practice is mostly to screen once a woman gets pregnant. With Counsyl's test, we can change the emphasis to pre-pregnancy screening when more options, including preimplantation genetic diagnosis, are available. Ideally, women should understand that having carrier testing before
pregnancy is as important as refraining from alcohol during pregnancy."
David Brenner, Director of the Dysautonomia Foundation: "As a parent of a child with a genetic disease, I wouldn't want another child to suffer from what my son has
endured. Nothing is more important than safeguarding the health of our children, and this test is such a simple and powerful way to prevent terrible suffering."
Rabbi David Wolpe of the Sinai Temple in Los Angeles: "Several years ago, a mother whose son was born with Tay-Sachs said to me sadly ‘The Rabbi made sure to tell us not to play Wagner's march at our wedding, but said nothing about being genetically tested.’ Ensuring that Jewish couples — and others — are offered genetic
testing is a critical task."
Professor Steven Pinker of Harvard University: "Universal genetic testing can drastically reduce the incidence of genetic diseases, and may very well eliminate many of them." Last year, Professor Pinker took the test with his wife, the novelist Rebecca Goldstein. To raise awareness of preventable genetic disease, they are now publicly announcing for the first time that both of them tested positive as carriers for familial dysautonomia. While they themselves are healthy, their children would have been at risk for this life-threatening genetic disease — underscoring that the value of genetic testing is far from hypothetical.
About Counsyl
The Universal Genetic Test was developed by Counsyl, a Stanford startup founded by social entrepreneurs and philanthropists. Counsyl's mission is to end the needless suffering of preventable genetic disease.
To ensure that every ounce of prevention enables a pound of cure, each test taken helps Counsyl fund treatments for children living with genetic disease. More than $50,000 has already been donated to nonprofits over the course of 2009. For the next month, donations will go to the John F. and Aileen A. Crowley Foundation in honor of John Crowley, the Harvard Business School graduate whose life is the basis
Genetic diseases like those seen in the new Harrison Ford movie "Extraordinary Measures" can now be prevented with a simple saliva test which is free with insurance for more than 100 million Americans.
The movie centers on the real-life efforts of the Crowleys, a family trying to find a cure for a rare genetic disease affecting two of the family’s three children. The condition wasn’t detected until after their children were born.
Now, couples can take a Universal Genetic Test before pregnancy to determine whether their baby is at risk for more than 100 life-threatening genetic diseases. At-risk couples may then use a well-understood procedure called IVF/PGD to protect their child from genetic disease and ensure a healthy pregnancy.
This Universal Genetic Test was invented by scientists and social entrepreneurs from Stanford and Harvard and brought to the public via a Stanford startup named Counsyl (counsyl.com). As Newsweek recently reported:
“What is the secret to improving public health while cutting costs? The question has consumed Washington, but it's being answered elsewhere, by doctors offering a new test for more than 100 rare recessive genes, some of which cause fatal diseases. The test, [offered by] Counsyl, lets potential parents assess their genomes to see if their future kids are at risk. ... This is as preventive as medicine gets: the test could eliminate all single-recessive-gene diseases.”
The test is now offered by physicians at more than 100 prestigious medical centers across the United States, including Yale Fertility Center (see counsyl.com/map), and has attracted the support of prominent academics, bioethicists,
religious leaders, families with genetic disease, and doctors from America’s largest hospitals.
Broad Support among Prominent Physicians for Universal Genetic TestingDr. Steven Ory, Past President of the American Society for Reproductive Medicine: "After 30 years in reproductive medicine, I am more optimistic about this development in genetic disease prevention than I've ever been before. The vast majority of babies born with genetic disease have no family history. That's why it's so critically important for all parents to get the Universal Genetic Test before pregnancy."
Dr. Pasquale Patrizio, Director of the Yale Fertility Center: "Every adult of reproductive age needs the Counsyl test. It is unusual in that it benefits all three parts of the health care triad: patients, doctors, and insurers. A child stricken by
preventable genetic disease often dies in infancy and costs the bereaved parents millions in medical bills. A five minute saliva test that prevents this is a money saver, a time saver, and most importantly a life saver; it really is a no-brainer."
Dr. Thomas Walsh, Director of the Male Fertility Laboratory at the University of Washington: "Genetic testing has been recommended for all adults before pregnancy since 2001, but like many topics related to planning a pregnancy, awareness of this
issue continues to lag. This test covers several key genetic diseases, including cystic fibrosis, spinal muscular atrophy, sickle cell, Tay-Sachs, and many others. The results of testing enable couples to make an informed decision before conceiving a child.”
Dr. John Marshall, Former Chairman of Ob/Gyn at Harbor-UCLA Medical Center: "Because the test can be taken in the privacy of one's home as well as in a clinical setting, it reminds me of the first 'at home pregnancy test'. This 'at home carrier test' is very similar in that the healthy adults who take it generally
test negative, with those who test positive referred for medical followup. It thus completely reshapes the debate over so-called direct-to-consumer or 'DTC' testing. Offering this test over the web as well as in a clinical setting is simply a moral imperative, as it is the only way to get needed care to people in rural areas who may be far away from large hospitals."
Dr. Michael Levy, Clinical Professor of Ob/Gyn at Georgetown & Director of IVF at Shady Grove Fertility, America's largest IVF center: "Parents who know their carrier status before pregnancy can take preventive measures to have a healthy
child. Because new techniques like PGD are used before pregnancy, they avoid the ethical dilemma of termination that was previously a roadblock to wider adoption of carrier testing."
The New Standard of Care at the Nation's Largest Fertility CentersDr. Angeline Beltsos, Medical Director of the Fertility Centers of Illinois: "Every doctor and patient wants to avoid a high-risk pregnancy. Yet many people don't know that
single gene disorders now account for more than 10% of infant deaths. The Universal Genetic Test is the next ultrasound: a non-invasive early warning system for couples to know if their baby is at risk."
Dr. Arthur Wisot, Medical Director of Reproductive Partners Medical Group in Los Angeles: "The Counsyl test is appropriate for everyone trying to conceive because it is the first test that makes it both practical and economical to screen for so
many genetic diseases. Couples can now protect their baby from developing any one of over a hundred debilitating and lethal genetic diseases with just a saliva sample. This test is the future of genetic screening."
Dr. Ian Hardy, Medical Director of Fertility Centers of New England: "We have been offering the Counsyl test to our incoming patients as part of their standard
evaluation with exceptional results. It is an easy-to-use saliva test which is covered by most insurance plans and allows couples to be screened for both common genetic diseases (like CF, SMA, PKU, and beta thalassemia) as well as dozens of rare conditions."
Dr. Kaylen Silverberg, Medical Director of Texas Fertility: "The Counsyl test replaces a battery of more expensive blood tests. It provides a couple and their physician with much more information for a fraction of the cost. Counsyl testing
represents a quantum leap forward in pre-pregnancy planning for couples — especially those concerned about having a child with a genetic disease — as it is safe, affordable, and easy to use."
Dr. Michael Soules, Medical Director of Seattle Reproductive Medicine: "The new Counsyl test is the simplest and most cost-effective way to do genetic screening as it checks for over 100 significant disorders with a single saliva sample. Enlightened insurance carriers are paying for this test as it saves them the major future expenses of covering a chronically sick child."
An Advance for Women, Minorities, and Families with Genetic Disease Professor Henry Louis Gates of Harvard University: "As the first genetic test for all ethnic groups, the Counsyl test represents a genuine breakthrough for minority health. With
one test for diverse communities, African Americans and Hispanics can benefit from a new technology that actually reduces health care disparities."
Elena Ashkinadze, Program Supervisor in Genetics, UMDNJ-Robert Wood Johnson Medical School: "Because Counsyl's test simultaneously covers diseases from many ethnic groups at a considerably lower cost than standard blood tests, it promises to make carrier testing affordable for previously underserved patient populations, including African Americans and Hispanics. The current practice is mostly to screen once a woman gets pregnant. With Counsyl's test, we can change the emphasis to pre-pregnancy screening when more options, including preimplantation genetic diagnosis, are available. Ideally, women should understand that having carrier testing before
pregnancy is as important as refraining from alcohol during pregnancy."
David Brenner, Director of the Dysautonomia Foundation: "As a parent of a child with a genetic disease, I wouldn't want another child to suffer from what my son has
endured. Nothing is more important than safeguarding the health of our children, and this test is such a simple and powerful way to prevent terrible suffering."
Rabbi David Wolpe of the Sinai Temple in Los Angeles: "Several years ago, a mother whose son was born with Tay-Sachs said to me sadly ‘The Rabbi made sure to tell us not to play Wagner's march at our wedding, but said nothing about being genetically tested.’ Ensuring that Jewish couples — and others — are offered genetic
testing is a critical task."
Professor Steven Pinker of Harvard University: "Universal genetic testing can drastically reduce the incidence of genetic diseases, and may very well eliminate many of them." Last year, Professor Pinker took the test with his wife, the novelist Rebecca Goldstein. To raise awareness of preventable genetic disease, they are now publicly announcing for the first time that both of them tested positive as carriers for familial dysautonomia. While they themselves are healthy, their children would have been at risk for this life-threatening genetic disease — underscoring that the value of genetic testing is far from hypothetical.
About Counsyl
The Universal Genetic Test was developed by Counsyl, a Stanford startup founded by social entrepreneurs and philanthropists. Counsyl's mission is to end the needless suffering of preventable genetic disease.
To ensure that every ounce of prevention enables a pound of cure, each test taken helps Counsyl fund treatments for children living with genetic disease. More than $50,000 has already been donated to nonprofits over the course of 2009. For the next month, donations will go to the John F. and Aileen A. Crowley Foundation in honor of John Crowley, the Harvard Business School graduate whose life is the basis
Tuesday, December 15, 2009
MALARIA PROGRESS REPORT SHOWS THAT DEVELOPMENT AID FOR HEALTH IS WORKING
Significant progress has been made in delivering life saving malaria nets and treatments over the past few years, but the coverage of malaria programmes needs to be stepped up drastically in order to meet the Millennium Development Goals (MDGs), according to a report released today by the World Health Organization (WHO).
The World Malaria Report 2009 found that the increase in international funding commitments (US$ 1.7 billion in 2009 compared to US$ 730 million in 2006) had allowed a dramatic scale up of malaria control interventions in several countries, along with measurable reductions in malaria burden. However, the amounts available still fall short of the US$ 5 billion required annually to ensure high coverage and maximal impact worldwide.
The WHO Director-General, Dr Margaret Chan, described the findings in the report as cause for cautious optimism and said "While much remains to be done, the data presented here clearly suggest that the tremendous increase in funding for malaria control is resulting in the rapid scale up of today's control tools. This, in turn, is having a profound effect on health - especially the health of children in sub-Saharan Africa. In a nutshell, development aid for health is working."
The report found that more life-saving malaria nets and treatments were delivered in 2007 and 2008 compared to 2006.
More African households (31%) own at least one insecticide-treated net (ITN), and more children under 5 years of age used an ITN in 2008 (24%) compared to previous years. These averages are affected by low ITN ownership in several large African countries for which resources for scale-up are only now being made available. Household ITN ownership reached more than 50% in 13 of the 35 highest burden African countries.
Use of artemisinin-based combination therapies (ACTs) is increasing but remains low in most African countries with fewer than 15% of children with fever receiving an ACT.
More than one-third of the 108 malarious countries (9 African countries and 29 outside of Africa) documented reductions in malaria cases of more than 50% in 2008 compared to 2000.
Where scale-up of proven interventions has occurred, and surveillance systems are functioning, remarkable impact has been documented:
In countries and areas that have achieved high coverage with bed nets and treatment programmes (e.g. Eritrea, Rwanda, Sao Tome and Principe, Zambia and Zanzibar, the United Republic of Tanzania) recorded cases and deaths due to malaria have fallen by 50% (target set by World Health Assembly for 2010) suggesting that MDG target for malaria can be achieved if there is adequate coverage of key interventions.
Large decreases in malaria cases and deaths have been mirrored by steep declines in all-cause deaths among children less than 5 years of age suggesting that intensive efforts at malaria control could help many African countries to reach, by 2015, a two-thirds reduction in child mortality as set forth in the MDGs.
High levels of external assistance were shown to be linked to decreases in malaria incidence. However, many external funds are concentrated on smaller countries with lower disease burdens. More attention needs to be given to ensuring success in large countries that account for most malaria cases and deaths.
Parasite resistance to anti-malarial medicines and mosquito resistance to insecticides are major threats to achieving global malaria control. Confirmation of artemisinin resistance was reported in 2009, and WHO is leading a major resistance containment effort in South East Asia. Key elements in the global strategy to prevent the spread of drug resistance include: 1) Rapidly reducing the spread of malaria using malaria preventive tools 2) ensuring that all malaria infections are correctly diagnosed, effectively treated and followed-up to ensure that they do not spread the disease to others 3) halting the marketing and use of oral artemisinin monotherapies and importantly, 4) carefully monitoring the efficacy of medicines to detect early evidence of resistance.
The report noted that there was urgent need for the global community to completely fund the Global Malaria Action Plan in order to sustain early success and achieve the 2015 MDGs. The African Region had the largest increase in funding of all regions, led by investments by the Global Fund, the U.S. President's Malaria Initiative, and other agencies.
The success of malaria control efforts will be in reducing the burden of malaria and improving child survival. Investing in malaria control is not only helping the world to reach the MDGs, but is also helping to build health systems that will ensure that these development gains are sustained.
The World Malaria Report 2009 found that the increase in international funding commitments (US$ 1.7 billion in 2009 compared to US$ 730 million in 2006) had allowed a dramatic scale up of malaria control interventions in several countries, along with measurable reductions in malaria burden. However, the amounts available still fall short of the US$ 5 billion required annually to ensure high coverage and maximal impact worldwide.
The WHO Director-General, Dr Margaret Chan, described the findings in the report as cause for cautious optimism and said "While much remains to be done, the data presented here clearly suggest that the tremendous increase in funding for malaria control is resulting in the rapid scale up of today's control tools. This, in turn, is having a profound effect on health - especially the health of children in sub-Saharan Africa. In a nutshell, development aid for health is working."
The report found that more life-saving malaria nets and treatments were delivered in 2007 and 2008 compared to 2006.
More African households (31%) own at least one insecticide-treated net (ITN), and more children under 5 years of age used an ITN in 2008 (24%) compared to previous years. These averages are affected by low ITN ownership in several large African countries for which resources for scale-up are only now being made available. Household ITN ownership reached more than 50% in 13 of the 35 highest burden African countries.
Use of artemisinin-based combination therapies (ACTs) is increasing but remains low in most African countries with fewer than 15% of children with fever receiving an ACT.
More than one-third of the 108 malarious countries (9 African countries and 29 outside of Africa) documented reductions in malaria cases of more than 50% in 2008 compared to 2000.
Where scale-up of proven interventions has occurred, and surveillance systems are functioning, remarkable impact has been documented:
In countries and areas that have achieved high coverage with bed nets and treatment programmes (e.g. Eritrea, Rwanda, Sao Tome and Principe, Zambia and Zanzibar, the United Republic of Tanzania) recorded cases and deaths due to malaria have fallen by 50% (target set by World Health Assembly for 2010) suggesting that MDG target for malaria can be achieved if there is adequate coverage of key interventions.
Large decreases in malaria cases and deaths have been mirrored by steep declines in all-cause deaths among children less than 5 years of age suggesting that intensive efforts at malaria control could help many African countries to reach, by 2015, a two-thirds reduction in child mortality as set forth in the MDGs.
High levels of external assistance were shown to be linked to decreases in malaria incidence. However, many external funds are concentrated on smaller countries with lower disease burdens. More attention needs to be given to ensuring success in large countries that account for most malaria cases and deaths.
Parasite resistance to anti-malarial medicines and mosquito resistance to insecticides are major threats to achieving global malaria control. Confirmation of artemisinin resistance was reported in 2009, and WHO is leading a major resistance containment effort in South East Asia. Key elements in the global strategy to prevent the spread of drug resistance include: 1) Rapidly reducing the spread of malaria using malaria preventive tools 2) ensuring that all malaria infections are correctly diagnosed, effectively treated and followed-up to ensure that they do not spread the disease to others 3) halting the marketing and use of oral artemisinin monotherapies and importantly, 4) carefully monitoring the efficacy of medicines to detect early evidence of resistance.
The report noted that there was urgent need for the global community to completely fund the Global Malaria Action Plan in order to sustain early success and achieve the 2015 MDGs. The African Region had the largest increase in funding of all regions, led by investments by the Global Fund, the U.S. President's Malaria Initiative, and other agencies.
The success of malaria control efforts will be in reducing the burden of malaria and improving child survival. Investing in malaria control is not only helping the world to reach the MDGs, but is also helping to build health systems that will ensure that these development gains are sustained.
Oncologist at Children's Hospital of Philadelphia to Chair International Childhood Cancer Organization
Will Lead Children's Oncology Group -- Collaborative Organization in Pediatric Cancer
Peter C. Adamson, M.D., a pediatric oncologist and leading scientist at The Children's Hospital of Philadelphia Research Institute, has been selected to lead the Children's Oncology Group (COG) in its efforts to find cures for children with cancer.
An internationally recognized leader in pediatric cancer drug development, Dr. Adamson will assume his new role with COG on Jan. 1, 2010. He was elected by principal investigators of more than 200 COG sites. COG unites more than 5,000 experts in childhood cancer at leading children's hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer.
Dr. Adamson, who came to The Children's Hospital of Philadelphia in 1999 from the National Cancer Institute, is the director of Clinical and Translational Research and chief of the Division of Clinical Pharmacology and Therapeutics at Children's Hospital. He also is a professor of Pediatrics and Pharmacology at the University of Pennsylvania School of Medicine. He will remain on the staff of Children's Hospital and on the Penn faculty while serving as COG chair.
Emerging research shows that even the more common childhood cancers are actually a mix of different diseases, each potentially requiring a different specific therapy. Creating such disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside, which Dr. Adamson will lead through expanding COG's role at Children's Hospital and fostering new and enhanced collaborations with COG sites throughout the world.
The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. www.chop.edu
The Cancer Center at The Children's Hospital of Philadelphia's large basic and clinical research programs are particularly strong in pediatric neuro-oncology, neuroblastoma, leukemia and lymphoma, and sarcomas.
Physicians at Children's Hospital have had pioneering roles in developing international standards for diagnosing and treating neuroblastoma, and in developing programs for survivors of childhood cancer.
Peter C. Adamson, M.D., a pediatric oncologist and leading scientist at The Children's Hospital of Philadelphia Research Institute, has been selected to lead the Children's Oncology Group (COG) in its efforts to find cures for children with cancer.
An internationally recognized leader in pediatric cancer drug development, Dr. Adamson will assume his new role with COG on Jan. 1, 2010. He was elected by principal investigators of more than 200 COG sites. COG unites more than 5,000 experts in childhood cancer at leading children's hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer.
Dr. Adamson, who came to The Children's Hospital of Philadelphia in 1999 from the National Cancer Institute, is the director of Clinical and Translational Research and chief of the Division of Clinical Pharmacology and Therapeutics at Children's Hospital. He also is a professor of Pediatrics and Pharmacology at the University of Pennsylvania School of Medicine. He will remain on the staff of Children's Hospital and on the Penn faculty while serving as COG chair.
Emerging research shows that even the more common childhood cancers are actually a mix of different diseases, each potentially requiring a different specific therapy. Creating such disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside, which Dr. Adamson will lead through expanding COG's role at Children's Hospital and fostering new and enhanced collaborations with COG sites throughout the world.
The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. www.chop.edu
The Cancer Center at The Children's Hospital of Philadelphia's large basic and clinical research programs are particularly strong in pediatric neuro-oncology, neuroblastoma, leukemia and lymphoma, and sarcomas.
Physicians at Children's Hospital have had pioneering roles in developing international standards for diagnosing and treating neuroblastoma, and in developing programs for survivors of childhood cancer.
Afghanistan first in world to use new vaccine against polio Critical step as global eradication effort faces entrenched challenges
A new vaccine against polio will be used for the first time today in polio immunization campaigns in Afghanistan. The bivalent oral polio vaccine (bOPV), recommended by the Advisory Committee on Poliomyelitis Eradication, the global technical advisory body of the Global Polio Eradication Initiative as a critical tool to eradicate polio, can provide the optimal concurrent protection needed by young children against both surviving serotypes (types 1 and 3) of the paralysing virus. This will vastly simplify the logistics of vaccination in the conflict-affected parts of this country. This sub-national immunization campaign, from 15-17 December, will deliver bOPV to 2.8 million children under five in the Southern, South-Eastern and Eastern Regions of Afghanistan. Of the three wild polioviruses (known as types 1, 2 and 3), type 2 has not been seen anywhere in the world since 1999. This achievement led to the development of monovalent vaccines, which provide protection against a single type with greater efficacy than the traditional trivalent vaccine. To determine whether a bivalent vaccine could effectively protect children living in areas where both types circulate, a clinical field trial completed in June 2009 compared bOPV with the existing vaccines. For both types 1 and 3 polio, bOPV was found to be at least 30% more effective than the trivalent vaccine and almost as good as the monovalent vaccines, yet in a package that could deliver both at once.
The bOPV allows countries to simplify vaccine logistics and to optimize protection using a mix of the available polio vaccines according to local needs. In southern Afghanistan, where access to children can be limited depending on the security situation, using bOPV helps maximise the impact of each contact with a child.
Most of Afghanistan is polio-free: 28 out of the 31 children paralysed by polio this year come from 13 highly insecure districts (of 329 districts in the country). In 2009, polio eradication efforts in Afghanistan have focused on improving operations and creating a safe environment for vaccination teams. Nongovernmental agencies have been contracted and local leaders involved to ensure that parties in conflict are approached, safe passage for vaccinators assured and children reached. Due to such preparations and strengthened supervision and staffing, the proportion of the nearly 1.2 million children under five years old in the Southern Region who could not be reached was reduced from more than 20% in early 2009, down to 5% during the July and September 2009 campaigns. The availability of bOPV multiplies the effect of such improvements. However, in the 13 highest-risk districts of Kandahar and Helmand provinces in the Southern Region, the proportion of children who are still unimmunized is well above 20% – and more than 60% in some areas.
Four countries in the world have never stopped polio transmission – Afghanistan, India, Nigeria and Pakistan. Types 1 and 3 polio circulate in limited parts of all these countries, and the others will follow Afghanistan's lead in using bOPV during the coming months, marking the adoption of a major new tool in the international effort to eradicate polio. While the Global Polio Eradication Initiative, a public-private partnership leading the effort, has reduced the incidence of polio by more than 99% (from an estimated 1000 children affected daily in 1988 to 1483 children in all of 2009 to date) polio still has a foothold in the four endemic countries. The consequences are severe beyond those areas: 16 previously polio-free countries are currently suffering outbreaks following importations of the virus; in four of these, polio transmission has lasted more than a year.
The availability of bOPV is part of a range of new and area-specific tactics in 2009 to reach eradication more quickly. The swift production of the vaccine was the result of extraordinary collaboration between the World Health Organization, UNICEF, vaccine manufacturers and regulatory agencies.
The vaccination campaign in Afghanistan is financed by the Government of Canada. Canada, which assumes presidency of the G8 in 2010, first placed polio on the group's agenda when it last held the presidency in 2002. The G8 is the single-largest donor bloc to polio eradication.
The Global Polio Eradication Initiative is spearheaded by the World Health Organization, Rotary International, the US Centers for Disease Control and Prevention and UNICEF.
The bOPV allows countries to simplify vaccine logistics and to optimize protection using a mix of the available polio vaccines according to local needs. In southern Afghanistan, where access to children can be limited depending on the security situation, using bOPV helps maximise the impact of each contact with a child.
Most of Afghanistan is polio-free: 28 out of the 31 children paralysed by polio this year come from 13 highly insecure districts (of 329 districts in the country). In 2009, polio eradication efforts in Afghanistan have focused on improving operations and creating a safe environment for vaccination teams. Nongovernmental agencies have been contracted and local leaders involved to ensure that parties in conflict are approached, safe passage for vaccinators assured and children reached. Due to such preparations and strengthened supervision and staffing, the proportion of the nearly 1.2 million children under five years old in the Southern Region who could not be reached was reduced from more than 20% in early 2009, down to 5% during the July and September 2009 campaigns. The availability of bOPV multiplies the effect of such improvements. However, in the 13 highest-risk districts of Kandahar and Helmand provinces in the Southern Region, the proportion of children who are still unimmunized is well above 20% – and more than 60% in some areas.
Four countries in the world have never stopped polio transmission – Afghanistan, India, Nigeria and Pakistan. Types 1 and 3 polio circulate in limited parts of all these countries, and the others will follow Afghanistan's lead in using bOPV during the coming months, marking the adoption of a major new tool in the international effort to eradicate polio. While the Global Polio Eradication Initiative, a public-private partnership leading the effort, has reduced the incidence of polio by more than 99% (from an estimated 1000 children affected daily in 1988 to 1483 children in all of 2009 to date) polio still has a foothold in the four endemic countries. The consequences are severe beyond those areas: 16 previously polio-free countries are currently suffering outbreaks following importations of the virus; in four of these, polio transmission has lasted more than a year.
The availability of bOPV is part of a range of new and area-specific tactics in 2009 to reach eradication more quickly. The swift production of the vaccine was the result of extraordinary collaboration between the World Health Organization, UNICEF, vaccine manufacturers and regulatory agencies.
The vaccination campaign in Afghanistan is financed by the Government of Canada. Canada, which assumes presidency of the G8 in 2010, first placed polio on the group's agenda when it last held the presidency in 2002. The G8 is the single-largest donor bloc to polio eradication.
The Global Polio Eradication Initiative is spearheaded by the World Health Organization, Rotary International, the US Centers for Disease Control and Prevention and UNICEF.
Saturday, November 21, 2009
International Diabetes Federation Drives Global Action Ahead of World Diabetes Day-November 14
November sees global celebrations to mark Diabetes Awareness Month
In many countries, November is diabetes awareness month, with November 14 - World Diabetes Day - the most significant date on the diabetes calendar.
The need to increase diabetes awareness grows ever year with the increasing impact of the disease worldwide. The latest data published by IDF in the 4th Edition of the Diabetes Atlas, show that 285 million people worldwide now live with diabetes. IDF predicts that, the total number will exceed 435 million in 2030(i) if the current rate of growth continues unchecked.
Ahead of World Diabetes Day, IDF President Professor Jean Claude Mbanya called for increased health promotion and political action in the face of the epidemic."Diabetes is claiming four million lives each year," he said. "It is ravaging communities and threatening economies. We must improve care and stop the many millions at risk from developing the disease. With a growing cost of over 376 billion dollars a year, either we make healthy life choices available and affordable now, or pay billions more tomorrow."
World Diabetes Day around the globe
Celebrated every year, World Diabetes Day is a campaign led by the International Diabetes Federation (IDF) and its more than 200 member associations in over 160 countries and territories. Created by IDF and the World Health Organization in 1991, World Diabetes Day became an official United Nations Day in 2007 thanks to a UN resolution that calls on all member states to organize events to mark the day.
This year sees the first of a five-year campaign that addresses the growing need for diabetes education and prevention programmes to tackle diabetes and its life-threatening complications. The World Diabetes Day campaign aims to establish access to diabetes education as a right for all people with diabetes, to promote greater awareness of the risk factors and warning signs of diabetes, and encourage best-practice sharing in diabetes prevention.
The International Diabetes Federation is calling on all countries to mark World Diabetes Day and increase diabetes awareness by lighting monuments around the world in blue - the colour of the blue circle, the global symbol for diabetes. More than 400 monuments and iconic buildings have already confirmed participation on November 14. They include: Table Mountain in South Africa, the London Eye in the United Kingdom, the Burj al Arab in the United Arab Emirates, Christ the Redeemer in Brazil, the Hofburg in Austria, the Alamo in the USA and Tokyo Tower in Japan. Across Japan close to 60 monuments will light in blue; 82 will light in Argentina, 34 in Kazakhstan and 21 in the USA.
In addition to the lightings, hundreds of events will take place worldwide to mark the day from individual acts of celebration and community-based activities, all the way up to regional events such as the Pan-African meeting in Mauritius that will see the launch of an African Declaration on diabetes.
The World Diabetes Day campaign can be followed online at www.worlddiabetesday.org; www.twitter.com/wdd; Facebook-http://tinyurl.com/o7o6kf and www.youtube.com/worlddiabetesday.
Note to Editors
About IDF
The International Diabetes Federation (IDF) is an umbrella organization of 212 member associations in than 163 countries and territories, representing over 285 million people with diabetes, their families, and their healthcare providers. The mission of IDF is to promote diabetes care, prevention and a cure worldwide. Its main activities include education for people with diabetes and healthcare professionals, public awareness campaigns and the promotion and exchange of information. IDF is a non-governmental organization in official relations with WHO and associated to the United Nations' Department of Public Information. For more information, please visit www.idf.org and follow us at twitter.com/IntDiabetesFed
About World Diabetes Day
World Diabetes Day is celebrated on 14 November, a date chosen to mark the birthday of Sir Frederick Banting, one of the pioneers in diabetes research. An official United Nation's Day, World Diabetes Day is represented by the blue circle logo that is the global symbol of diabetes. The World Diabetes Day campaign is supported by 14 official partners: Abbott Diabetes Care, AstraZeneca, Boston Scientific, Bristol-Myers Squibb, LifeScan, Eli Lilly, Medtronic, Merck Sharp & Dohme (MSD), Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis and Takeda.
(i)IDF Diabetes Atlas 4th Edition, International Diabetes Federation, 2009. www.diabetesatlas.org
In many countries, November is diabetes awareness month, with November 14 - World Diabetes Day - the most significant date on the diabetes calendar.
The need to increase diabetes awareness grows ever year with the increasing impact of the disease worldwide. The latest data published by IDF in the 4th Edition of the Diabetes Atlas, show that 285 million people worldwide now live with diabetes. IDF predicts that, the total number will exceed 435 million in 2030(i) if the current rate of growth continues unchecked.
Ahead of World Diabetes Day, IDF President Professor Jean Claude Mbanya called for increased health promotion and political action in the face of the epidemic."Diabetes is claiming four million lives each year," he said. "It is ravaging communities and threatening economies. We must improve care and stop the many millions at risk from developing the disease. With a growing cost of over 376 billion dollars a year, either we make healthy life choices available and affordable now, or pay billions more tomorrow."
World Diabetes Day around the globe
Celebrated every year, World Diabetes Day is a campaign led by the International Diabetes Federation (IDF) and its more than 200 member associations in over 160 countries and territories. Created by IDF and the World Health Organization in 1991, World Diabetes Day became an official United Nations Day in 2007 thanks to a UN resolution that calls on all member states to organize events to mark the day.
This year sees the first of a five-year campaign that addresses the growing need for diabetes education and prevention programmes to tackle diabetes and its life-threatening complications. The World Diabetes Day campaign aims to establish access to diabetes education as a right for all people with diabetes, to promote greater awareness of the risk factors and warning signs of diabetes, and encourage best-practice sharing in diabetes prevention.
The International Diabetes Federation is calling on all countries to mark World Diabetes Day and increase diabetes awareness by lighting monuments around the world in blue - the colour of the blue circle, the global symbol for diabetes. More than 400 monuments and iconic buildings have already confirmed participation on November 14. They include: Table Mountain in South Africa, the London Eye in the United Kingdom, the Burj al Arab in the United Arab Emirates, Christ the Redeemer in Brazil, the Hofburg in Austria, the Alamo in the USA and Tokyo Tower in Japan. Across Japan close to 60 monuments will light in blue; 82 will light in Argentina, 34 in Kazakhstan and 21 in the USA.
In addition to the lightings, hundreds of events will take place worldwide to mark the day from individual acts of celebration and community-based activities, all the way up to regional events such as the Pan-African meeting in Mauritius that will see the launch of an African Declaration on diabetes.
The World Diabetes Day campaign can be followed online at www.worlddiabetesday.org; www.twitter.com/wdd; Facebook-http://tinyurl.com/o7o6kf and www.youtube.com/worlddiabetesday.
Note to Editors
About IDF
The International Diabetes Federation (IDF) is an umbrella organization of 212 member associations in than 163 countries and territories, representing over 285 million people with diabetes, their families, and their healthcare providers. The mission of IDF is to promote diabetes care, prevention and a cure worldwide. Its main activities include education for people with diabetes and healthcare professionals, public awareness campaigns and the promotion and exchange of information. IDF is a non-governmental organization in official relations with WHO and associated to the United Nations' Department of Public Information. For more information, please visit www.idf.org and follow us at twitter.com/IntDiabetesFed
About World Diabetes Day
World Diabetes Day is celebrated on 14 November, a date chosen to mark the birthday of Sir Frederick Banting, one of the pioneers in diabetes research. An official United Nation's Day, World Diabetes Day is represented by the blue circle logo that is the global symbol of diabetes. The World Diabetes Day campaign is supported by 14 official partners: Abbott Diabetes Care, AstraZeneca, Boston Scientific, Bristol-Myers Squibb, LifeScan, Eli Lilly, Medtronic, Merck Sharp & Dohme (MSD), Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis and Takeda.
(i)IDF Diabetes Atlas 4th Edition, International Diabetes Federation, 2009. www.diabetesatlas.org
Subscribe to:
Posts (Atom)